GSK (LON:GSK) Receives "Underweight" Rating from JPMorgan Chase & Co.

GSK (LON:GSK - Get Free Report)'s stock had its "underweight" rating reiterated by analysts at JPMorgan Chase & Co. in a research note issued to investors on Wednesday, MarketBeat.com reports.

A number of other brokerages have also recently commented on GSK. Berenberg Bank lowered their target price on GSK from GBX 1,820 ($23.22) to GBX 1,600 ($20.41) and set a "buy" rating for the company in a report on Friday, November 29th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and issued a GBX 1,850 ($23.60) price objective on shares of GSK in a research note on Tuesday, September 3rd. Finally, Shore Capital reaffirmed a "buy" rating on shares of GSK in a research note on Wednesday, August 28th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, GSK has an average rating of "Moderate Buy" and an average target price of GBX 1,805.83 ($23.04).

GSK Trading Down 1.8 %

LON:GSK traded down GBX 24.75 ($0.32) during trading hours on Wednesday, reaching GBX 1,348.75 ($17.21). 15,119,753 shares of the stock were exchanged, compared to its average volume of 10,042,368. GSK has a twelve month low of GBX 1,282.50 ($16.36) and a twelve month high of GBX 1,823.50 ($23.26). The business has a 50-day moving average of GBX 1,414.54 and a two-hundred day moving average of GBX 1,533.52. The company has a market capitalization of £55.03 billion, a price-to-earnings ratio of 1,193.36, a PEG ratio of 1.24 and a beta of 0.31. The company has a quick ratio of 0.73, a current ratio of 0.82 and a debt-to-equity ratio of 123.04.

Insiders Place Their Bets

In related news, insider Elizabeth (Liz) McKee Anderson bought 446 shares of the company's stock in a transaction that occurred on Monday, September 23rd. The shares were purchased at an average cost of GBX 2,051 ($26.16) per share, with a total value of £9,147.46 ($11,669.17). Also, insider Jonathan Symonds purchased 7,150 shares of the business's stock in a transaction that occurred on Wednesday, October 30th. The shares were bought at an average price of GBX 1,394 ($17.78) per share, for a total transaction of £99,671 ($127,147.60). Insiders bought 7,604 shares of company stock worth $10,893,038 in the last 90 days. Corporate insiders own 1.61% of the company's stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.